Saphnelo (anifrolumab-fnia) / BMS, AstraZeneca - LARVOL DELTA

Understanding the Assumptions on Anifrolumab Dose Regimen Selection for a Phase 3 Trial in Lupus Nephritis. (PubMed, Clin Pharmacol Ther) - No abstract available

Journal • P3 data • Glomerulonephritis • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology

Targeting the Type I Interferon Pathway: Efficacy and Safety of Anifrolumab in Refractory Juvenile Dermatomyositis-A Multi-Center Experience (ACR Convergence 2026) - "Before beginning anifrolumab infusions, all patients received prednisone, IVIG, and at least two other immunosuppressive agents (Table 1). Anifrolumab demonstrated promising efficacy in this cohort of 6 patients with refractory JDM, resulting in clinically meaningful improvement in cutaneous and overall disease activity. The favorable safety profile, with no adverse effects reported in any patient, is encouraging. Type I interferon signature normalization in patients with available paireddata provides biological evidence of successful IFNAR1 blockade and support the mechanistic rationale for anifrolumabuse in JDM."

Clinical • Dermatomyositis • Gastrointestinal Disorder • Immunology • Inflammatory Arthritis • Lupus • Metabolic Disorders • Myositis • Systemic Lupus Erythematosus • IFNAR1

Early Treatment Pathways Improve Outcomes in Severe Autoimmune Diseases: Systematic Review and Evidence Synthesis of 430 Studies (ACR Convergence 2026) - "Rituximab maintenance therapy significantly reduced relapse compared with azathioprine (HR 0.36, 95% CI 0.23-0.57), while avacopan-based protocols achieved sustained remission in 71.0% versus 56.1% of patients receiving conventional glucocorticoid regimens (difference 12.5%, 95% CI 2.6-22.3; p=0.007). In EGPA, mepolizumab significantly increased remission rates (OR 12.0, 95% CI 2.7-53.0). In SSc-ILD, nintedanib reduced annual forced vital capacity decline by 41 mL/year and multiple trials demonstrated preservation of pulmonary function with cyclophosphamide-, mycophenolate-, and tocilizumab-based treatment protocols. In SLE, anifrolumab improved BICLA response rates versus placebo (59.4% vs 43.9%; p=0.02), while lupus nephritis studies demonstrated significant reductions in adverse renal outcomes (HR 0.12, 95% CI 0.031-0.39).Overall, evidence supporting morbidity reduction (184 studies) exceeded evidence for mortality reduction (122 studies), indicating that prevention..."

Review • ANCA Vasculitis • Dermatomyositis • Eosinophilic Granulomatosis With Polyangiitis • Glomerulonephritis • Immunology • Inflammatory Arthritis • Interstitial Lung Disease • Langerhans Cell Histiocytosis • Lupus • Lupus Nephritis • Myositis • Nephrology • Pulmonary Disease • Rare Diseases • Respiratory Diseases • Scleroderma • Systemic Sclerosis • Vasculitis • IFIH1

LUB006, A Novel and Potent anti-IFNAR1-TACI Antibody Fusion Protein, Demonstrates Synergistic Efficacy in an Systemic Lupus Erythematosus Model by Dual Pathway Inhibition (ACR Convergence 2026) - "The pharmacokinetics (PK), pharmacodynamics (PD) and GLP toxicology study (14-week repeated-dose) of LUB006 were evaluated in cynomolgus monkeys. LUB006 displayed superior BAFF/APRIL binding affinity and blocking activity to Telitacicept and Povetacicept, and comparable IFNAR1 binding affinity and pSTAT1 inhibition to that of Anifrolumab. LUB006 exhibited superior activity against BAFF/APRIL in both in vitro assays and an in vivo PD model compared to competitors. Additionally, we demonstrated the synergistic benefit of dual-pathway inhibition in suppressing B cell proliferation and in a bm12-inducible lupus model. These preclinical findings suggest that LUB006 may offer enhanced therapeutic efficacy for SLE and other autoimmune diseases."

Clinical • Immunology • Inflammatory Arthritis • Lupus • Sjogren's Syndrome • Systemic Lupus Erythematosus • IFNA1 • IFNAR1

Recombinant Zoster Vaccine Protects Against Both Herpes Zoster and COVID-19 Infection in SLE Patients on Anifrolumab (ACR Convergence 2026) - No abstract available

Clinical • Herpes Zoster • Infectious Disease • Inflammatory Arthritis • Novel Coronavirus Disease • Varicella Zoster

Monitoring the Biological Response to Anifrolumab in Real World Setting Using Interferon Gene Signature Shows Signs of Therapy Resistance in Select SLE Patients (ACR Convergence 2026) - No abstract available

Clinical • Gene Signature • Real-world • Real-world evidence • Inflammatory Arthritis

Clinical Phenotypes, Disease Activity Outcomes, and Glucocorticoid Use Among Belimumab- and Anifrolumab-Treated Patients With Non-Renal SLE (ACR Convergence 2026) - No abstract available

Clinical • Inflammatory Arthritis

Multicenter Real-World Registry of Anifrolumab (ANIFRO-REU) in Systemic Lupus Erythematosus: Effectiveness in Patients with Articular and Cutaneous Manifestations with up to 12 Months of Follow-up (ACR Convergence 2026) - No abstract available

Clinical • Real-world • Real-world evidence • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus

Anifrolumab versus Belimumab for Cardiovascular Disease Risk in Systemic Lupus Erythematosus (ACR Convergence 2026) - No abstract available

Cardiovascular • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus

Population Pharmacokinetics and Exposure-Response Analyses of Subcutaneous and Intravenous Anifrolumab in Patients With Systemic Lupus Erythematosus (ACR Convergence 2026) - No abstract available

Clinical • PK/PD data • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus

Real-world Effectiveness of Anifrolumab in Adults with SLE: A 3-Month Interim Analysis of a Multinational Prospective Observational Cohort (ACR Convergence 2026) - No abstract available

Clinical • Observational data • Real-world • Real-world effectiveness • Real-world evidence • Inflammatory Arthritis

Anifrolumab Treatment Prevents Long-Term Oral Corticosteroid-Related, Ocular, and Musculoskeletal Organ Damage Accrual Compared With Real-World Standard of Care in Patients With Systemic Lupus Erythematosus: Findings From the LASER Study (ACR Convergence 2026) - No abstract available

Clinical • Real-world • Real-world evidence • Immunology • Inflammatory Arthritis • Lupus • Musculoskeletal Diseases • Systemic Lupus Erythematosus

Glucocorticoid Dose Reduction and Low Flare Rates in Patients with SLE Receiving Anifrolumab in Routine Practice: 12-Month Interim Analysis of a Multinational Observational Real-World Study (ACR Convergence 2026) - No abstract available

Clinical • Real-world • Real-world evidence • Inflammatory Arthritis

Patient-Reported Outcomes After 12 Months of Real-World Anifrolumab Treatment: Interim Results From a Multinational, Real-World Study (ACR Convergence 2026) - No abstract available

Clinical • Patient reported outcomes • Real-world • Real-world evidence • Immunology • Lupus • Systemic Lupus Erythematosus

Reduced Glucocorticoid Use in Patients With SLE Receiving Intravenous/Subcutaneous Anifrolumab Versus Placebo: Pooled Data From Phase 3 Clinical Trials (ACR Convergence 2026) - No abstract available

Clinical • P3 data • Inflammatory Arthritis

Improvements in SLE Disease Activity Across Multiple Organ Systems with Intravenous and Subcutaneous Anifrolumab Treatment: Pooled Analysis of 3 Phase 3 Trials (ACR Convergence 2026) - No abstract available

P3 data • Retrospective data • Inflammatory Arthritis

Efficacy of Anifrolumab Treatment in Improving Joint Outcomes: Pooled Data from Intravenous and Subcutaneous Phase 3 Trials (ACR Convergence 2026) - No abstract available

Clinical • P3 data • Immunology • Lupus • Systemic Lupus Erythematosus

Remission and Lupus Low Disease Activity State Attainment and Glucocorticoid Reduction without Increasing Flares with Anifrolumab in Asian patients with Systemic Lupus Erythematosus: A Post Hoc Analysis from a Phase III Study (ACR Convergence 2026) - No abstract available

Clinical • P3 data • Retrospective data • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus

Efficacy of Anifrolumab Across Multiple Organ Systems in Patients with Moderate to Severe Systemic Lupus Erythematosus: A Post-Hoc Analysis of the Phase III AZALEA trial (ACR Convergence 2026) - No abstract available

Clinical • P3 data • Retrospective data • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus

An Interferon-Independent Stromal-Humoral Niche Persists Following Anifrolumab Therapy in Cutaneous Lupus Erythematosus (ACR Convergence 2026) - "While anifrolumab effectively suppresses IFN-driven inflammation in CLE, persistent plasma cells within CCL19⁺BAFF⁺ fibroblast niches reveal an IFN-independent mechanism of treatment resistance. Functional studies implicate LTα-driven non-canonical NF-κB signaling in maintaining these stromal-humoral survival niches, supporting combination strategies to achieve durable remission in refractory CLE."

Stroma • Cutaneous Lupus Erythematosus • Immunology • Infectious Disease • Inflammatory Arthritis • Lupus • CCL19 • CXCL10 • IFNAR1 • IFNB1 • IFNG • TNFA

Anifrolumab Treatment is Associated With DORIS-0 Remission in Adults With Systemic Lupus Erythematosus: Real-World Outcomes From an Academic Lupus Registry (ACR Convergence 2026) - No abstract available

Clinical • Real-world • Real-world evidence • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus

Anifrolumab Treatment is Associated With Lupus Low Disease Activity State in Adults With Systemic Lupus Erythematosus: Real-World Outcomes From an Academic Lupus Registry (ACR Convergence 2026) - No abstract available

Clinical • Real-world • Real-world evidence • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus

Organ-Specific Treatment Response: Real-World Mucocutaneous and Musculoskeletal Outcomes After 6 and 12 Months of Anifrolumab Treatment (ACR Convergence 2026) - No abstract available

Clinical • Real-world • Real-world evidence • Musculoskeletal Diseases

Treatment Adherence in Patients with SLE Receiving Anifrolumab in Routine Practice: 12-Month Interim Analysis of a Multinational Observational Real-World Study (ACR Convergence 2026) - No abstract available

Adherence • Clinical • Real-world • Real-world evidence • Inflammatory Arthritis

Real-World Effectiveness and Safety of Anifrolumab Therapy: A Multicenter Collaboration (ACR Convergence 2026) - No abstract available

Clinical • Real-world • Real-world effectiveness • Real-world evidence • Immunology • Lupus • Systemic Lupus Erythematosus